Opinion/decision on a Paediatric investigation plan (PIP): Skyrizi,Risankizumab, decision type: , therapeutic area: , PIP number: P/0497/2022

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness